Advanced Filters
noise

cytomegalovirus-infections Clinical Trials

A listing of cytomegalovirus-infections medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 80 clinical trials
L Laurence BUISSIERES, PhD

Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Versus Valaciclovir

The investigators' hypothesis is that maternal treatment with Letermovir will inhibit fetal CMV replication better than Valaciclovir in infected fetuses and lead to a higher proportion of negative CMV PCR at birth in neonatal blood collected in the first day of life or in cord blood in case of termination …

18 years of age Female Phase 3
A Arsenio Spinillo, MD

Immunological and Virological Prognostic Markers of Human Cytomegalovirus (HCMV) Congenital Infection in Pregnant Women With Primary HCMV Infection.

Human cytomegalovirus (HCMV) establishes a lifelong relationship with its host: primary infection is followed by a latency phase with intermittent reactivation episodes, despite a robust, long-lasting immune response. Primary and non-primary infection (the latter indicating both reactivation and re-infection) is usually asymptomatic in immunocompetent individuals. Apart from immunocompromised subjects, HCMV …

18 years of age Female Phase N/A
D Dominique Bertrand, MD

Effectiveness of an Immune-guided Cytomegalovirus Infection Preventive Strategy Compared to a Universal Prophylactic Strategy in Renal Transplant Patients

Cytomegalovirus (CMV) establishes a chronic infection in 60% of the general population. In renal transplant recipients, it is responsible for morbidities occurring mainly in the first 6 months after transplantation. These include viral reactivations linked to immunosuppressive treatment inhibiting the anti-CMV T lymphocyte response. CMV infection, a sign of uncontrolled …

18 - 75 years of age All Phase 3
X Xiaoyu Zhu, PhD

Effect of Letermovir Prophylaxis on CMV-specific Immune Reconstitution Post UCBT

To explore the effect of letermovir prophylaxis on cytomegalovirus-specific immune reconstitution post unrelated cord blood transplantation

years of age All Phase N/A

CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS

Human immunodeficiency virus type 1 (HIV-1) causes a persistent infection that ultimately leads to acquired immunodeficiency syndrome (AIDS). Treatment of HIV-1 infection with combination anti-retroviral therapy (ART) suppresses HIV-1 replication to undetectable viral levels and saves lives. Nevertheless, ART cannot eradicate latent cellular reservoirs of the virus, and HIV-1 infection …

18 years of age All Phase 0
C Charlotte CL LAURENT, Doctor

Evolution of CMV Antiviral T-cell Immunity Over the Next Six Months Initiation of Treatment With Belatacept.

Belatacept inhibits T cell activation by blocking the costimulatory signal. In kidney transplantation, it limits the use of anticalcineurins while ensuring a satisfactory level of immunosuppression.

18 years of age All Phase N/A
F Fareed Khawaja, M D

The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients

The goal of this laboratory research study is to learn if interrupting a patient's letermovir dosing based on their immune system response can help HSC transplant patients avoid post-treatment CMV infections better than taking letermovir every day without interruption.

18 years of age All Phase N/A
R Robert Wynn, MD FRCPath

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

The main aim of this study is to find out the safety, tolerability and pharmacokinetics (PK) of maribavir for the treatment of CMV infection in children and teenagers after HSCT or SOT and to identify the optimal dose of maribavir using a 200 milligrams (mg) tablet formulation or powder for …

- 17 years of age All Phase 3
B Bendedicte Neven, Prof.

Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections

Haematopoietic stem cell transplantation (HSCT) can expose patients to a transient but marked immunosuppression, during which viral infections are an important cause of morbidity and mortality. Adoptive transfer of virus-specific T cells is an attractive approach to restore protective T-cell immunity in patients with refractory viral infections after allogeneic HSCT. …

2 years of age All Phase 3
H HA Nguyen Thi Thu, PhD.MD

Congenital CYtoMEgalovirus Infection in VIEtnam (CYMEVIE)

To estimate the prevalence of congenital CMV infection in Vietnamese neonates and relating morbidity within 2-year follow-up. Along with evaluating the predictive value of the presence and the level of CMV replication in the first trimester in a highly seropositive population

18 years of age All Phase N/A

Simplify language using AI